assistant professor, cancer immunologist, bioinformatics and cancer genomics
New York, USA
Joined December 2020
- Tweets75
- Following86
- Followers58
- Likes24
Vladimir Roudko retweeted
Just heard the brilliant news that AlphaFold was awarded the lasker award- congratulation to Deemis Hassabis & team for a well deserved recognition laskerfoundation.org/winners…
Vladimir Roudko retweeted
Today we launch the next generation of AI oncology company with the support of great investors @hardimanjames @DCVC, @dreidco @ZettaVentures, 11.2, Intermountain Ventures, Epic Ventures, Catalio, North South Ventures, @viswacolluru @RecursionChris.
businesswire.com/news/home/2…
Vladimir Roudko retweeted
New generation of cancer-preventing vaccines enter early clinical trials for healthy people at high risk for disease #cancer #Immunotherapy
science.org/content/article/…
Vladimir Roudko retweeted
Storing and analyzing a genome on a blockchain genomebiology.biomedcentral.…
Vladimir Roudko retweeted
The @bernstein_lab is now on #Twitter! Follow us for lab updates and news on cancer epigenetics!!
🧬🔬
Vladimir Roudko retweeted
New updated analysis by the team at @CancerResearch in collaboration with @IQVIA_global of the PD1/PDL1 clinical trial landscape, including use of approved therapies in the clinic and a summary of new anti-PD1/PDL1 treatment modalities go.nature.com/3HIpHPm
Great news!
.@MountSinaiNYC has announced a transformative multimillion-dollar gift from Marc Lipschultz, who serves on Mount Sinai’s Boards of Trustees, and his wife, Jennifer, to the Precision Immunology Institute (PrIISM) at @IcahnMountSinai: mshs.co/2uR
Vladimir Roudko retweeted
The new @EMBL Programme has launched!
We're proud to be a part of @EMBL and we're looking forward to contributing our #bioinformatics expertise to this exciting new scientific programme that ushers in a new era in the life sciences.
EMBL embarks on a new era of molecular biology.
EMBL research will expand to study life in context – from molecules to ecosystems. Broad in scope, our next programme encompasses fundamental research, services & multidisciplinary collaboration.
embl.org/news/lab-matters/a-…
Vladimir Roudko retweeted
A study evaluating effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine against the #Omicron variant indicates a third dose neutralizes Omicron at a similar order of magnitude as was observed after two doses of the vaccine against wild-type #SARSCoV2. fcld.ly/d9noexp
Specialized ribosomes go immune! Role of protein translation in immunotherapy response and evasion gets first recognition.
Group leaders Pia Kvistborg and William Faller received an ASPIRE award from the Mark Foundation. With it, they can dive into a brand new research field, chasing down ribosomes - the protein factories in the cells that may be sabotaging immunotherapy ➡️ bit.ly/3nyak46
Vladimir Roudko retweeted
MEFISTO is out in Nature Methods - a framework for dimension reduction and integration of multi-modal omics data with temporal or spatial resolution. Paper at nature.com/articles/s41592-0…, highlights in the thread below. (1/7)
Vladimir Roudko retweeted
(1) Finally out, after one of the most painful and long reviews (with nitpicky reviews, see my last comment) is a method that I am extremely proud of and excited about. One of the best in my career: nature.com/articles/s41592-0…
How does that even make any sense?
In this scenario, the cost of publication is covered by an Article Processing Charge (APC) paid at the time of publication. The APC for Nature Neuroscience in 2022 is €9,500/US $11,390/£8,290.
Vladimir Roudko retweeted
Excited to share my work from @DASLab_MSKCC lab out today in @nchembio where we develop CAR-T cells that produce small molecule drugs at the tumor site. This is an exciting step forward in the utilization of engineered cells for drug delivery! nature.com/articles/s41589-0…
Vladimir Roudko retweeted
Studying ~56 million T cells from 55 COVID patients, researchers in @SciImmunology offer a high-res picture of epitope reactivity and TCR usage in CD8 T cells specific for #SARSCoV2, some of which also react to “common cold” coronaviruses. fcld.ly/s5bda4r
Vladimir Roudko retweeted
Highly recommended review! 🤯😍😍👏
Germinal Centre Shutdown frontiersin.org/article/10.3…
Vladimir Roudko retweeted
A new method developed to reread a single polypeptide many times overcomes one of the biggest obstacles toward single-molecule proteomics.
Read more in a new #SciencePerspective: fcld.ly/23d7ov4
Vladimir Roudko retweeted
Findings from the KEYNOTE-522 trial show the addition of the immunotherapy agent pembrolizumab to chemotherapy before surgery decreased the recurrence by almost 40% in patients with early triple-negative breast cancer. #TNBC
bit.ly/3yXPUGd
Vladimir Roudko retweeted
Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis dlvr.it/SFrY1K